Literature DB >> 20390054

Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Qin Li1, Kristina K Peachman, Laurie Sower, Stephen H Leppla, Sathish B Shivachandra, Gary R Matyas, Johnny W Peterson, Carl R Alving, Mangala Rao, Venigalla B Rao.   

Abstract

We describe a novel hybrid anthrax toxin approach that incorporates multiple components into a single vaccine product. The key domains of protective antigen (PA) and lethal factor (LF) that may be critical for inducing protective immunity are combined into one recombinant molecule. Two LF N-terminal domain-PA hybrids, one with wild-type PA and another with furin cleavage-minus PA, were expressed in E. coli and purified in a native form. Both the hybrids bind to the extracellular domain of the host receptor, CMG2; the wild-type hybrid can be cleaved by furin exposing the LF interacting domain, allowing it to oligomerize into lethal toxin as well as translocation pore-like complexes. The hybrid antigens are immunogenic in Dutch-belted rabbits, eliciting strong PA-specific and LF-specific antibodies. However, the lethal toxin neutralizing antibody titers are 3-7 times lower than those elicited by PA-alum. The hybrid antigens conferred 100% (6/6) protection in rabbits challenged intranasally with a 100 LD(50) dose of Bacillus anthracis Ames strain spores.

Entities:  

Year:  2009        PMID: 20390054      PMCID: PMC2853182          DOI: 10.2174/1875035400902010092

Source DB:  PubMed          Journal:  Open Vaccine J


  47 in total

1.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

2.  Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production.

Authors:  F C BELTON; R E STRANGE
Journal:  Br J Exp Pathol       Date:  1954-04

3.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Authors:  Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

5.  Optimized production and purification of Bacillus anthracis lethal factor.

Authors:  S Park; S H Leppla
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

6.  Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein.

Authors:  B M Price; A L Liner; S Park; S H Leppla; A Mateczun; D R Galloway
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

7.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

Review 8.  The roles of anthrax toxin in pathogenesis.

Authors:  Mahtab Moayeri; Stephen H Leppla
Journal:  Curr Opin Microbiol       Date:  2004-02       Impact factor: 7.934

9.  Detoxified lethal toxin as a potential mucosal vaccine against anthrax.

Authors:  Qingfu Xu; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2008-02-06

10.  Needle-free skin patch vaccination method for anthrax.

Authors:  Gary R Matyas; Arthur M Friedlander; Gregory M Glenn; Stephen Little; Jianmei Yu; Carl R Alving
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

View more
  9 in total

Review 1.  Adjuvants for human vaccines.

Authors:  Carl R Alving; Kristina K Peachman; Mangala Rao; Steven G Reed
Journal:  Curr Opin Immunol       Date:  2012-04-19       Impact factor: 7.486

2.  Highly effective generic adjuvant systems for orphan or poverty-related vaccines.

Authors:  Mangala Rao; Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Richard Borschel; Venee I Morthole; Carmen Fernandez-Prada; Carl R Alving; Venigalla B Rao
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

3.  Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.

Authors:  Julie A Lovchik; Melissa Drysdale; Theresa M Koehler; Julie A Hutt; C Rick Lyons
Journal:  Infect Immun       Date:  2012-04-23       Impact factor: 3.441

4.  A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine.

Authors:  Gaobing Wu; Yuzhi Hong; Aizhen Guo; Chunfang Feng; Sha Cao; Cheng-Cai Zhang; Ruiping Shi; Yadi Tan; Ziduo Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

5.  Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Authors:  Kristina K Peachman; Qin Li; Gary R Matyas; Sathish B Shivachandra; Julie Lovchik; Rick C Lyons; Carl R Alving; Venigalla B Rao; Mangala Rao
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

6.  Quantitative Determination of Lethal Toxin Proteins in Culture Supernatant of Human Live Anthrax Vaccine Bacillus anthracis A16R.

Authors:  Xiaodong Zai; Jun Zhang; Ju Liu; Jie Liu; Liangliang Li; Ying Yin; Ling Fu; Junjie Xu; Wei Chen
Journal:  Toxins (Basel)       Date:  2016-02-25       Impact factor: 4.546

7.  Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.

Authors:  Mary-Ann Elvina Xavier; Shihui Liu; Thomas H Bugge; Julia Baguña Torres; Michael Mosley; Samantha L Hopkins; Phillip D Allen; Georgina Berridge; Iolanda Vendrell; Roman Fischer; Veerle Kersemans; Sean Smart; Stephen H Leppla; Bart Cornelissen
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

Review 8.  Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor.

Authors:  Catherine H Schein; Deliang Chen; Lili Ma; John J Kanalas; Jian Gao; Maria Estrella Jimenez; Laurie E Sower; Mary A Walter; Scott R Gilbertson; Johnny W Peterson
Journal:  Toxins (Basel)       Date:  2012-11-08       Impact factor: 4.546

9.  Constructing and transient expression of a gene cassette containing edible vaccine elements and shigellosis, anthrax and cholera recombinant antigens in tomato.

Authors:  Jafari Davod; Dehghan Nayeri Fatemeh; Hossein Honari; Ramin Hosseini
Journal:  Mol Biol Rep       Date:  2018-09-22       Impact factor: 2.316

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.